These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16149605)

  • 21. [CA15-3].
    Inaji H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():651-3. PubMed ID: 16149603
    [No Abstract]   [Full Text] [Related]  

  • 22. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers].
    Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [DU-PAN-2, SPan-1].
    Motoo Y; Sawabu N
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():687-90. PubMed ID: 16149612
    [No Abstract]   [Full Text] [Related]  

  • 24. [Detection of CA 125 in the serum and tissue of patients with ovarian neoplasms].
    Kristen P; Beier HJ; Kaesemann H; Caffier H
    Gynakol Rundsch; 1989; 29 Suppl 2():358-60. PubMed ID: 2693257
    [No Abstract]   [Full Text] [Related]  

  • 25. [Fundamental and clinical evaluation of immunoradiometric assay (IRMA) for serum pancreatic oncofetal antigen (POA)].
    Ohba N; Hashimoto T; Nishibu M; Kashiwaya Y; Kawai K; Matsubara F; Miyazaki I
    Rinsho Byori; 1989 Feb; 37(2):153-8. PubMed ID: 2733181
    [No Abstract]   [Full Text] [Related]  

  • 26. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
    Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
    Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of circulating sialyl Tn antigen in colorectal cancer patients.
    Nakagoe T; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Kurosaki N; Yasutake T; Ayabe H; Tagawa Y
    Anticancer Res; 2000; 20(5C):3863-9. PubMed ID: 11268468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [High CA-125 values in a patient with miliary tuberculosis and ascites].
    Klein M; Marczewski A; Rosen A; Beck A
    Gynakol Rundsch; 1989; 29 Suppl 2():355-6. PubMed ID: 2613049
    [No Abstract]   [Full Text] [Related]  

  • 29. [Squamous cell carcinoma antigen].
    Nawata S; Sugino N; Kato H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():684-6. PubMed ID: 16149611
    [No Abstract]   [Full Text] [Related]  

  • 30. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [KMO1].
    Kamigaki T; Kuroda Y
    Nihon Rinsho; 1999 Dec; 57 Suppl():517-9. PubMed ID: 10778178
    [No Abstract]   [Full Text] [Related]  

  • 32. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
    Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
    Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
    [No Abstract]   [Full Text] [Related]  

  • 35. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
    Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
    Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor markers in ovarian carcinoma.
    Dudzinski MR
    Curr Opin Obstet Gynecol; 1990 Feb; 2(1):52-6. PubMed ID: 2102306
    [No Abstract]   [Full Text] [Related]  

  • 37. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Serum level of tumor markers (antigen Ca 19-9, CEA, ferritin) in digestive tumors. Their diagnostic usefulness].
    Jovin G; Stănel I; Popovici I; Oproiu A
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(3):223-9. PubMed ID: 2904162
    [No Abstract]   [Full Text] [Related]  

  • 39. [Urinary BTA (bladder tumor antigen)].
    Shimetani N; Mori M
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():782-4. PubMed ID: 16149640
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical significance of Span-1 antigen assay as a tumor marker].
    Satake K; Chung YS; Umeyama K
    Nihon Rinsho; 1990 Feb; 48 Suppl():1053-6. PubMed ID: 2355504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.